Livanova

OverviewSuggest Edit

LivaNova is a global medical technology company. The company provides cardiac surgery, neuromodulation, and cardiac rhythm management solutions.

TypePublic
Founded2015
HQLondon, GBMap
Websitelivanova.com
Employee Ratings3.7More
View Jobs (193)

Recent NewsAll News

Latest Updates

Employees (est.) (May 2021)4,000
Job Openings193
Revenue (FY, 2020)$934.2 M(-13%)
Share Price (Jun 2021)$80.1(+2%)
Cybersecurity ratingCMore

Key People/Management at Livanova

Damien McDonald

Damien McDonald

Chief Executive Officer and Director
Daniel Moore

Daniel Moore

Chairman
Francesco Bianchi

Francesco Bianchi

Director
Keyna Skeffington

Keyna Skeffington

Senior Vice President, General Counsel
William Kozy

William Kozy

Director
Hugh Morrison

Hugh Morrison

Director
Show more

Livanova Office Locations

Livanova has offices in London, Brockworth, Houston, Dandenong South and in 16 other locations
London, GB (HQ)
20 Eastbourne Terrace
Brockworth, GB
1370, Montpellier Court, Gloucester Business Park
Dandenong South, AU
16/18 Hydrive Cl
Wien, AT
Schottengasse 1
Markham, CA
280 Hillmount Rd #8
Bogotá, CO
Cra. 33 ##15-39
Show all (21)

Livanova Financials and Metrics

Livanova Revenue

Livanova's revenue was reported to be $934.24 m in FY, 2020
USD

Revenue (Q1, 2021)

247.6m

Gross profit (Q1, 2021)

168.4m

Gross profit margin (Q1, 2021), %

68%

Net income (Q1, 2021)

(29.7m)

EBIT (Q1, 2021)

(4.4m)

Market capitalization (4-Jun-2021)

3.9b

Closing stock price (4-Jun-2021)

80.1

Cash (31-Mar-2021)

252.5m

EV

4.4b
Livanova's current market capitalization is $3.9 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

415.7m1.2b1.0b1.1b1.1b934.2m

Cost of goods sold

149.2m472.0m353.4m361.8m308.1m

Gross profit

266.5m741.9m658.9m745.1m626.2m

Gross profit Margin, %

64%61%65%67%67%
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

287.0m321.0m295.3m285.1m321.4m309.7m250.4m287.5m272.1m250.8m277.2m268.6m242.4m182.2m240.1m247.6m

Cost of goods sold

123.6m130.7m106.5m101.5m108.9m108.2m84.6m92.0m94.3m84.3m74.9m86.1m68.9m56.8m86.5m79.2m

Gross profit

163.4m190.4m188.8m183.6m212.5m201.4m165.8m195.5m177.8m166.5m202.2m182.5m173.5m125.4m153.6m168.4m

Gross profit Margin, %

57%59%64%64%66%65%66%68%65%66%73%68%72%69%64%68%
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

112.6m39.8m93.6m47.2m61.1m252.8m

Accounts Receivable

272.4m275.7m282.1m256.1m257.8m184.4m

Prepaid Expenses

26.6m60.5m39.0m29.6m28.6m24.8m

Inventories

212.4m183.5m144.5m153.5m164.2m126.7m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

87.5m63.9m63.6m62.7m42.7m65.2m65.0m47.4m79.9m50.8m44.5m75.3m125.8m232.5m227.8m252.5m

Accounts Receivable

76.0k288.5m299.6m284.3m271.5m305.4m314.0m279.8m261.9m252.3m247.1m256.1m243.2m225.3m186.1m191.9m180.7m

Prepaid Expenses

38.6m51.8m51.9m56.0m49.2m55.2m31.1m35.6m37.7m34.3m24.9m22.5m42.4m34.8m32.0m28.8m

Inventories

210.8m192.7m197.6m192.4m204.7m214.6m154.3m157.8m153.1m161.3m168.7m167.8m170.3m177.2m178.1m124.5m
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(29.6m)(62.8m)(25.1m)(189.4m)(155.2m)(345.0m)

Depreciation and Amortization

20.5m45.5m37.1m69.9m70.7m67.3m

Inventories

36.3m26.7m7.2m(10.6m)(10.6m)1.4m

Cash From Operating Activities

(9.3m)90.2m91.3m120.5m(91.1m)(79.4m)
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2020Q1, 2021

Net Income

1.0k(40.4m)(31.4m)(33.0m)11.3m58.8m86.6m13.3m28.3m21.2m(14.8m)(44.1m)(11.9m)37.6m(65.2m)(29.7m)

Depreciation and Amortization

23.6m41.7m34.0m20.2m41.1m63.3m17.1m35.2m53.0m16.9m33.8m52.8m17.1m51.6m12.8m

Inventories

10.8m24.7m20.6m(4.4m)(6.9m)(11.0m)(6.3m)(11.3m)(7.6m)(8.3m)(14.3m)(18.2m)(12.5m)(12.1m)(2.9m)

Cash From Operating Activities

9.6m12.6m49.3m33.2m31.6m73.7m20.4m48.5m99.6m2.0m(17.4m)(94.0m)(106.0m)(116.4m)19.5m
show all
USDQ3, 2015

Financial Leverage

1 x
Show all financial metrics

Livanova Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

Learn more about our premium products
SecurityScorecard logo

Livanova Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Livanova Online and Social Media Presence

Livanova's Trends

Embed Graph

Livanova News and Updates

December 01, 2020

Epilepsy Market Driven By LivaNova, GlaxoSmithKline, GW Pharmaceuticals, Abbott Laboratories

Epilepsy is a central nervous system (neurological) disorder in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness. Posted via Industry Today. Follow us on Twitter @IndustryToday
October 13, 2020

PrimeStone Capital - Lettre au conseil d'administration de LivaNova PLC

LONDRES, 13 octobre 2020 /PRNewswire/ -- PrimeStone Capital LLP, un actionnaire détenant environ 2,2 % de LivaNova PLC, a envoyé une lettre ouverte au conseil d'administration de la société. Vous pouvez trouver la lettre ici : http://www.primestonecapital.com/livanova Pour plus...
October 12, 2020

PrimeStone Capital - Letter to the Board of Directors of LivaNova PLC

LONDON, Oct. 12, 2020 /PRNewswire/ -- PrimeStone Capital LLP, a shareholder with a ca.2.2% holding in LivaNova PLC, has sent a public letter to the Board of Directors of the Company. You can find the letter here: http://www.primestonecapital.com/livanova For more information on PrimeStone...
January 17, 2020

Focus on Sleep Apnea Implant Market Changing the Way of Business in Upcoming Year with Profiling Key Nyxoah, LivaNova, Invacare

The global Sleep Apnea Implant market is valued at XX million USD in 2020 and is expected to reach XX million USD by the end of 2026, growing at a CAGR of XX% between 2020 and 2026. Posted via Industry Today. Follow us on Twitter @IndustryToday
November 20, 2019

LivaNova to restructure heart valve unit

Medical device maker LivaNova Plc said on Wednesday it will restructure its heart valve business that could impact about 150 employees in three of its facilities.
May 02, 2019

Global Heart Valve Repair and Replacement Devices Market to 2023 - Key Vendors are Abbott, Boston Scientific, CryoLife, Edwards Lifesciences, LivaNova, & Medtronic

DUBLIN, May 2, 2019 /PRNewswire/ -- The "Global Heart Valve Repair and Replacement Devices Market 2019-2023" report has been added to ResearchAndMarkets.com's offering. The analysts have predicted that the heart valve repair and replacement devices market will register a CAGR of nearly...
Show more

Livanova Blogs

June 15, 2021

LivaNova Receives FDA Approval for Clinical Study to Evaluate the aura6000 System to Treat Obstructive Sleep Apnea

Company to launch OSPREY investigational device exemption clinical study in the U.S. LONDON --(BUSINESS WIRE)--Jun. 15, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has received approval from the U.S.
June 01, 2021

LivaNova Completes Initial Closing of Heart Valve Business to Gyrus Capital

LivaNova Completes Initial Closing of Heart Valve Business to Gyrus Capital Katherine.Howe… Tue, 06/01/2021 - 05:30 LivaNova Completes Initial Closing of Heart Valve Business to Gyrus Capital Jun 01, 2021 This release is a backfill from a News Wire …
May 13, 2021

LivaNova to Present at the UBS Global Healthcare Virtual Conference

LivaNova to Present at the UBS Global Healthcare Virtual Conference Katherine.Howe… Thu, 05/13/2021 - 09:01 LivaNova to Present at the UBS Global Healthcare Virtual Conference May 13, 2021 This release is a backfill from a News Wire General …
April 28, 2021

LivaNova Reports First Quarter 2021 Results

LONDON --(BUSINESS WIRE)--Apr. 28, 2021-- LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2021 . For the first quarter of 2021, worldwide sales from continuing operations were $247.6 million , an
April 26, 2021

LivaNova and Verily Announce First Patient Enrolled in Study to Evaluate Treatment Effectiveness for Patients Living with Depression

LivaNova and Verily Announce First Patient Enrolled in Study to Evaluate Treatment Effectiveness for Patients Living with Depression Katherine.Howe… Mon, 04/26/2021 - 09:01 LivaNova and Verily Announce First Patient Enrolled in Study to Evaluate Treatment Effectiveness for Patients Living …
April 20, 2021

LivaNova Receives FDA 510(k) Clearance for B-Capta, the New In-Line, Blood-Gas Monitoring System Integrated Into the S5 Heart-Lung Machine

Intuitive, optical-based technology system now available around the world LONDON --(BUSINESS WIRE)--Apr. 20, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for
Show more

 Livanova Frequently Asked Questions

  • When was Livanova founded?

    Livanova was founded in 2015.

  • Who are Livanova key executives?

    Livanova's key executives are Damien McDonald, Daniel Moore and Francesco Bianchi.

  • How many employees does Livanova have?

    Livanova has 4,000 employees.

  • What is Livanova revenue?

    Latest Livanova annual revenue is $934.2 m.

  • What is Livanova revenue per employee?

    Latest Livanova revenue per employee is $233.6 k.

  • Who are Livanova competitors?

    Competitors of Livanova include Edwards Lifesciences, Zimmer Biomet and CryoLife.

  • Where is Livanova headquarters?

    Livanova headquarters is located at 20 Eastbourne Terrace, London.

  • Where are Livanova offices?

    Livanova has offices in London, Brockworth, Houston, Dandenong South and in 16 other locations.

  • How many offices does Livanova have?

    Livanova has 21 offices.